Health-related quality of life outcomes with prasugrel among medically managed non-ST-segment elevation acute coronary syndrome patients: Insights from the TRILOGY ACS trial

Abstract Background Few studies have assessed treatment effects on health-related quality of life (HRQoL) in patients with acute coronary syndrome (ACS) treated without revascularization. The TRILOGY ACS trial randomized patients with ACS to either prasugrel or clopidogrel therapy plus aspirin. Outc...

Full description

Saved in:
Bibliographic Details
Published in:The American heart journal 2015
Main Authors: Kaul, Padma, PhD, Ohman, E. Magnus, MD, Knight, J. David, MS, Anstrom, Kevin J., PhD, Roe, Matthew T., MD, MHS, Boden, William E., MD, Hochman, Judith S., MD, Gašparović, Vladimir, MD, Armstrong, Paul W., MD, McCollam, Patrick, PharmD, Fakhouri, Walid, PhD, Cowper, Patricia, PhD, Davidson-Ray, Linda, MA, Clapp-Channing, Nancy, MPH, White, Harvey D., MB, ChB, DSc, Fox, Keith A.A., MB, ChB, Prabhakaran, Dorairaj, MD, DM, MSc, Mark, Daniel B., MD, MPH
Format: Article
Language:English
Subjects:
Cardiovascular
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background Few studies have assessed treatment effects on health-related quality of life (HRQoL) in patients with acute coronary syndrome (ACS) treated without revascularization. The TRILOGY ACS trial randomized patients with ACS to either prasugrel or clopidogrel therapy plus aspirin. Outcomes showed a complex pattern suggestive of late benefits with respect to repeat clinical events and benefits confined to patients who underwent angiography. Here, we examine the HRQoL correlates of these patterns. Methods HRQoL was measured at baseline and 3, 12, and 24 months or end of study (EOS) in 7243 patients aged
ISSN:0002-8703
DOI:10.1016/j.ahj.2016.03.017